Skip to main content
Premium Trial:

Request an Annual Quote

Archer Reveal ctDNA Assay

ArcherDX has launched its Archer Reveal ctDNA assay which includes full-exon coverage of the tumor suppressor TP53 as a general marker of malignancy. It was designed for high-throughput laboratories and utilizes the company's lyophilized reagents and automated bioinformatics analysis. The assay generates NGS libraries using a little as 1ng circulating, cell-free tumor DNA and requires only 5 million paired-end reads. It is also very fast and can easily generate over 24 different libraries in less than 7 hours, the company said.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.